These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21135702)

  • 21. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
    Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care.
    Nguyen GC; Nugent Z; Shaw S; Bernstein CN
    Gastroenterology; 2011 Jul; 141(1):90-7. PubMed ID: 21458455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
    Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).
    Henriksen M; Jahnsen J; Lygren I; Aadland E; Schulz T; Vatn MH; Moum B;
    Scand J Gastroenterol; 2007 May; 42(5):602-10. PubMed ID: 17454881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
    Actis GC; Pellicano R; Bugianesi E; Lagget M; Rizzetto M
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):239-42. PubMed ID: 18614972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time trend and risk factors for reoperation in Crohn's disease in Japan.
    Watanabe T; Sasaki I; Sugita A; Fukushima K; Futami K; Hibi T; Watanabe M
    Hepatogastroenterology; 2012 Jun; 59(116):1081-6. PubMed ID: 22580659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.
    Lakatos PL; Golovics PA; David G; Pandur T; Erdelyi Z; Horvath A; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Veres G; Lovasz BD; Szathmari M; Kiss LS; Lakatos L
    Am J Gastroenterol; 2012 Apr; 107(4):579-88. PubMed ID: 22233693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.
    Cosnes J; Nion-Larmurier I; Beaugerie L; Afchain P; Tiret E; Gendre JP
    Gut; 2005 Feb; 54(2):237-41. PubMed ID: 15647188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.